8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Anne Boerekamps; Thomas Vanwolleghem; Marc van der Valk; Guido E. van den Berk; Marjo van Kasteren; Dirk Posthouwer; Anthonius S. M. Dofferhoff; Bart van Hoek; Dewkoemar Ramsoekh; Jelle Koopsen; Janke Schinkel; Eric Florence; Joop E. Arends; Bart J. Rijnders

doi:10.1016/j.jhep.2018.10.032

8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Anne Boerekamps
, Thomas Vanwolleghem
, Marc van der Valk
, Guido E. van den Berk
, Marjo van Kasteren
, Dirk Posthouwer
, Anthonius S. M. Dofferhoff
, Bart van Hoek
, Dewkoemar Ramsoekh
, Jelle Koopsen
, Janke Schinkel
, Eric Florence
, Joop E. Arends
, Bart J. Rijnders^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	554-557
Number of pages	4
Journal	Journal of Hepatology
Volume	70
Issue number	3
DOIs	https://doi.org/10.1016/j.jhep.2018.10.032
Publication status	Published - Mar 2019

Keywords

HEPATITIS-C
LEDIPASVIR

Access to Document

10.1016/j.jhep.2018.10.032

Cite this

Boerekamps, A., Vanwolleghem, T., van der Valk, M., van den Berk, G. E., van Kasteren, M., Posthouwer, D., Dofferhoff, A. S. M., van Hoek, B., Ramsoekh, D., Koopsen, J., Schinkel, J., Florence, E., Arends, J. E., & Rijnders, B. J. (2019). 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). Journal of Hepatology, 70(3), 554-557. https://doi.org/10.1016/j.jhep.2018.10.032

@article{a6ab9e29071e4d74b9dd5ef37ab3b97a,

title = "8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)",

keywords = "HEPATITIS-C, LEDIPASVIR",

author = "Anne Boerekamps and Thomas Vanwolleghem and \{van der Valk\}, Marc and \{van den Berk\}, \{Guido E.\} and \{van Kasteren\}, Marjo and Dirk Posthouwer and Dofferhoff, \{Anthonius S. M.\} and \{van Hoek\}, Bart and Dewkoemar Ramsoekh and Jelle Koopsen and Janke Schinkel and Eric Florence and Arends, \{Joop E.\} and Rijnders, \{Bart J.\}",

note = "Funding Information: AB: has nothing to disclose. TV: reports grants from Foundation Against Cancer Belgium (No. 2014-087), during the conduct of the study; non-financial support from Roche Diagnostics, grants from Gilead Sciences, grants from Bristol-Myers-Squibb, grants from Janssen, outside the submitted work; and Advisory Board membership for Abbvie, Gilead, Janssen and BMS. MvdV: reports grants and other from Abbvie, grants and other from Gilead, grants and other from Johnson \& Johnson, grants, non-financial support and other from MSD, other from ViiV, outside the submitted work. GvdB: has nothing to disclose. MvK: has nothing to disclose. DP: reports personal fees from Luminex – MTE session, outside the submitted work. AD: has nothing to disclose. BvH: reports personal fees from Bristol-Meyers Squibb, personal fees from Merck, personal fees from Abbvie, personal fees from Norgine, for advisory boards outside the submitted work. DR: reports grants from AbbVie, personal fees from Abbvie, personal fees from Abbvie, personal fees from Bristol Myers Squib, outside the submitted work. JK: has nothing to disclose. JS: reports grants from Gilead Sciences, grants from Abbvie, grants from MSD, grants from Janssen Pharmaceuticals, outside the submitted work. EF: reports grants from Janssen, grants from BMS, grants from Gilead, grants from ViiV Healthcare, other from Janssen, other from ViiV Healthcare, outside the submitted work. JA: reports other from Gilead Sciences, other from MSD, other from Janssen, other from Abbvie, other from ViiV, grants from Abbvie, grants from MSD, grants from ViiV, grants from MSD, outside the submitted work. BR: reports grants from MSD, during the conduct of the study; grants from Gilead, other from MSD, Jansen-Cilag, BMS, Gilead, Pfizer, ViiV, outside the submitted work. Funding Information: AB: has nothing to disclose. TV: reports grants from Foundation Against Cancer Belgium (No. 2014-087 ), during the conduct of the study; non-financial support from Roche Diagnostics, grants from Gilead Sciences, grants from Bristol-Myers-Squibb , grants from Janssen, outside the submitted work; and Advisory Board membership for Abbvie , Gilead, Janssen and BMS. MvdV: reports grants and other from Abbvie, grants and other from Gilead, grants and other from Johnson \& Johnson, grants, non-financial support and other from MSD, other from ViiV, outside the submitted work. GvdB: has nothing to disclose. MvK: has nothing to disclose. DP: reports personal fees from Luminex – MTE session, outside the submitted work. AD: has nothing to disclose. BvH: reports personal fees from Bristol-Meyers Squibb, personal fees from Merck, personal fees from Abbvie, personal fees from Norgine, for advisory boards outside the submitted work. DR: reports grants from AbbVie, personal fees from Abbvie, personal fees from Abbvie, personal fees from Bristol Myers Squib, outside the submitted work. JK: has nothing to disclose. JS: reports grants from Gilead Sciences, grants from Abbvie, grants from MSD, grants from Janssen Pharmaceuticals , outside the submitted work. EF: reports grants from Janssen, grants from BMS, grants from Gilead, grants from ViiV Healthcare , other from Janssen, other from ViiV Healthcare, outside the submitted work. JA: reports other from Gilead Sciences, other from MSD, other from Janssen, other from Abbvie, other from ViiV, grants from Abbvie, grants from MSD, grants from ViiV, grants from MSD, outside the submitted work. BR: reports grants from MSD, during the conduct of the study; grants from Gilead, other from MSD, Jansen-Cilag, BMS, Gilead, Pfizer, ViiV, outside the submitted work. ",

year = "2019",

month = mar,

doi = "10.1016/j.jhep.2018.10.032",

language = "English",

volume = "70",

pages = "554--557",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

number = "3",

}

Boerekamps, A, Vanwolleghem, T, van der Valk, M, van den Berk, GE, van Kasteren, M, Posthouwer, D, Dofferhoff, ASM, van Hoek, B, Ramsoekh, D, Koopsen, J, Schinkel, J, Florence, E, Arends, JE & Rijnders, BJ 2019, '8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)', Journal of Hepatology, vol. 70, no. 3, pp. 554-557. https://doi.org/10.1016/j.jhep.2018.10.032

TY - JOUR

T1 - 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

AU - Boerekamps, Anne

AU - Vanwolleghem, Thomas

AU - van der Valk, Marc

AU - van den Berk, Guido E.

AU - van Kasteren, Marjo

AU - Posthouwer, Dirk

AU - Dofferhoff, Anthonius S. M.

AU - van Hoek, Bart

AU - Ramsoekh, Dewkoemar

AU - Koopsen, Jelle

AU - Schinkel, Janke

AU - Florence, Eric

AU - Arends, Joop E.

AU - Rijnders, Bart J.

N1 - Funding Information: AB: has nothing to disclose. TV: reports grants from Foundation Against Cancer Belgium (No. 2014-087), during the conduct of the study; non-financial support from Roche Diagnostics, grants from Gilead Sciences, grants from Bristol-Myers-Squibb, grants from Janssen, outside the submitted work; and Advisory Board membership for Abbvie, Gilead, Janssen and BMS. MvdV: reports grants and other from Abbvie, grants and other from Gilead, grants and other from Johnson & Johnson, grants, non-financial support and other from MSD, other from ViiV, outside the submitted work. GvdB: has nothing to disclose. MvK: has nothing to disclose. DP: reports personal fees from Luminex – MTE session, outside the submitted work. AD: has nothing to disclose. BvH: reports personal fees from Bristol-Meyers Squibb, personal fees from Merck, personal fees from Abbvie, personal fees from Norgine, for advisory boards outside the submitted work. DR: reports grants from AbbVie, personal fees from Abbvie, personal fees from Abbvie, personal fees from Bristol Myers Squib, outside the submitted work. JK: has nothing to disclose. JS: reports grants from Gilead Sciences, grants from Abbvie, grants from MSD, grants from Janssen Pharmaceuticals, outside the submitted work. EF: reports grants from Janssen, grants from BMS, grants from Gilead, grants from ViiV Healthcare, other from Janssen, other from ViiV Healthcare, outside the submitted work. JA: reports other from Gilead Sciences, other from MSD, other from Janssen, other from Abbvie, other from ViiV, grants from Abbvie, grants from MSD, grants from ViiV, grants from MSD, outside the submitted work. BR: reports grants from MSD, during the conduct of the study; grants from Gilead, other from MSD, Jansen-Cilag, BMS, Gilead, Pfizer, ViiV, outside the submitted work. Funding Information: AB: has nothing to disclose. TV: reports grants from Foundation Against Cancer Belgium (No. 2014-087 ), during the conduct of the study; non-financial support from Roche Diagnostics, grants from Gilead Sciences, grants from Bristol-Myers-Squibb , grants from Janssen, outside the submitted work; and Advisory Board membership for Abbvie , Gilead, Janssen and BMS. MvdV: reports grants and other from Abbvie, grants and other from Gilead, grants and other from Johnson & Johnson, grants, non-financial support and other from MSD, other from ViiV, outside the submitted work. GvdB: has nothing to disclose. MvK: has nothing to disclose. DP: reports personal fees from Luminex – MTE session, outside the submitted work. AD: has nothing to disclose. BvH: reports personal fees from Bristol-Meyers Squibb, personal fees from Merck, personal fees from Abbvie, personal fees from Norgine, for advisory boards outside the submitted work. DR: reports grants from AbbVie, personal fees from Abbvie, personal fees from Abbvie, personal fees from Bristol Myers Squib, outside the submitted work. JK: has nothing to disclose. JS: reports grants from Gilead Sciences, grants from Abbvie, grants from MSD, grants from Janssen Pharmaceuticals , outside the submitted work. EF: reports grants from Janssen, grants from BMS, grants from Gilead, grants from ViiV Healthcare , other from Janssen, other from ViiV Healthcare, outside the submitted work. JA: reports other from Gilead Sciences, other from MSD, other from Janssen, other from Abbvie, other from ViiV, grants from Abbvie, grants from MSD, grants from ViiV, grants from MSD, outside the submitted work. BR: reports grants from MSD, during the conduct of the study; grants from Gilead, other from MSD, Jansen-Cilag, BMS, Gilead, Pfizer, ViiV, outside the submitted work.

PY - 2019/3

Y1 - 2019/3

KW - HEPATITIS-C

KW - LEDIPASVIR

U2 - 10.1016/j.jhep.2018.10.032

DO - 10.1016/j.jhep.2018.10.032

M3 - Comment/Letter to the editor

C2 - 30527953

SN - 0168-8278

VL - 70

SP - 554

EP - 557

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 3

ER -